Flexion Therapeutics prices IPO at $13 midpoint

By Renaissance Capital,

Shutterstock photo

Flexion Therapeutics, which is developing sustained-release injectable pain therapies for osteoarthritis, raised $65 million by offering 5.0 million shares at $13, within the range of $12 to $14. Flexion Therapeutics plans to list on the NASDAQ under the symbol FLXN. Flexion Therapeutics initially filed confidentially on 8/2/2013. BMO Capital Markets and Wells Fargo Securities acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: FLXN

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com